Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

GlobeNewswire August 9, 2021

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Newsfile July 27, 2021

Algernon Pharmaceuticals (CSE:AGN) reaches 70 per cent enrollment target for its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Brieanna McCutcheon  July 7, 2021

Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire July 7, 2021

Algernon Pharmaceuticals (CSE:AGN) will not be advancing its clinical trial of Ifenprodil for COVID-19

Jocelyn Aspa July 6, 2021

Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

GlobeNewswire July 6, 2021

The StockTalk Cannabis Report: June 25, 2021

Dave Jackson June 25, 2021

Algernon Pharmaceuticals (CSE:AGN) targets first human study of its psychedelic drug DMT for Q4, 2021

John Ballem  June 17, 2021

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

GlobeNewswire June 17, 2021

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

GlobeNewswire June 3, 2021

Algernon Pharmaceuticals Shares an Animal Study that Confirms the Effectiveness of DMT in Treating Stroke

John Ballem  May 28, 2021

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

GlobeNewswire May 27, 2021

Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from U.S. FDA for its DMT clinical research program

John Ballem  May 17, 2021

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

GlobeNewswire May 17, 2021

Algernon Pharmaceuticals Inc. Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

John Ballem  May 12, 2021

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

GlobeNewswire May 12, 2021

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire May 11, 2021

Algernon Pharmaceuticals (CSE:AGN) files end of Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 26, 2021

Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

GlobeNewswire April 26, 2021

Algernon Pharmaceuticals (CSE:AGN) to file End-of-Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 8, 2021